Ramesh Kumar bought stock once, on Apr 26, 2017

Ramesh Kumar is a biopharmaceuticals executive and corporate director who has served as a Director of Ocugen, Inc. and its subsidiary Ocugen OpCo, Inc. since 2019.( At Ocugen he has held roles as Independent Director and Chair of the Audit Committee, contributing oversight in finance, governance, and strategic direction for the company’s gene-therapy focused operations.( He has been an active corporate insider at Ocugen, reporting multiple equity transactions in the company’s stock over the past several years.(

Kumar’s career spans more than three decades in life sciences, including co‑founding and serving as CEO of Onconova Therapeutics, Inc., a biotechnology company focused on oncology, from 1998 to 2019.( He is also noted as the founder and former CEO of Traws Pharma, Inc., and previously held director and scientific roles at DNX Biotherapeutics/Nextran, Bristol‑Myers Squibb, and the National Cancer Institute, as well as a leadership position in genomics and transgenics at Kimeragen, Inc.( Kumar holds a Ph.D. in Molecular Biology from the University of Illinois (University of Illinois at the Medical Center) and completed his undergraduate and graduate studies at Panjab University, Chandigarh, grounding his executive career in a strong scientific and research background.(

Written by Perplexity from public sources.